Drugs / NanoPac®
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT04221828 | Oct 2020 → Jan 2021 | prostate adenocarcinoma | NanOlogy, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03077685 | Dec 2017 → Mar 2023 | pancreatic adenocarcinoma | NanOlogy, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03077659 | Sep 2017 → Oct 2018 | prostate adenocarcinoma | NanOlogy, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03029585 | Apr 2017 → Nov 2019 | ovarian carcinoma | NanOlogy, LLC | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| — | NCT03756311 Background | — | lung cancer, prostate cancer | NanOlogy, LLC | No longer available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanoPac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03077659 ↗ |
| Route | Other | “administered intraperitoneally (IP)” NCT03029585 ↗ |